Retrospective Study
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Sep 15, 2022; 14(9): 1785-1797
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1785
Table 1 General data of the patients
Variables

Sex, n (%)
Male7 (46.7)
Female8 (53.3)
Age (yr)55.53 ± 7.89
Body mass index, kg/m222.29 ± 2.94
Resectability, n (%)
Borderline resectable (n)7 (46.7)
Advanced pancreatic cancer (n)8 (53.3)
ASA grade, n (%)
I13 (86.7)
II2 (13.3)
Chemotherapy regimen, n (%)
AG13 (86.7)
Modified FOLFIRINOX2 (13.3)
ECOG score, n (%)
011 (73.3)
12 (13.35)
22 (13.35)
Chemotherapy cycle4 ± 1
Response to chemotherapy
PR15 (100%)
CR0
Tumor diameter before chemotherapy (cm)4.17 ± 1.40
Tumor diameter before surgery (cm)3.03 ± 1.13
Tumor regression (%)28.40 ± 9.71
CA19-9 level before chemotherapy (U/mL)736.25 (8.44-1200.00)1
CA19-9 level before surgery (U/mL)51.85 (4.81-341.3)1
Decrease in CA19-9 level (%)57.07 ± 32.07
Total count of CTCs before chemotherapy (n)16 (13-26)1
Total count of CTCs before surgery (n)7.13 ± 2.88
Decrease in the total number of CTCs (%)65.33 ± 12.09